{"id":9431,"date":"2026-09-14T12:41:24","date_gmt":"2026-09-14T10:41:24","guid":{"rendered":"https:\/\/mumak.me\/?p=9431"},"modified":"2026-09-14T15:30:00","modified_gmt":"2026-09-14T13:30:00","slug":"bayer-update-roundup-hearing-moves-into-focus","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/company-update\/bayer-update-roundup-hearing-moves-into-focus\/","title":{"rendered":"Bayer Update: Roundup Hearing Moves into Focus"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The Bayer stock<\/a> gained around 3% on Monday, September 14,<\/strong> and approached the EUR 50<\/strong> mark again ahead of a key US court hearing related to the Roundup litigation<\/strong>.<\/p>

The hearing in Missouri begins today and addresses the final approval of a class action settlement for Roundup lawsuits<\/strong>. Bayer has indicated that the court’s decision is expected at a later date and not immediately following the hearing.<\/p>

For Bayer, which remains a position within the UMBRELLA Strategy<\/strong>, one of the company’s most important remaining legal risks thus moves back into focus.<\/p>

Roundup Litigation Remains in Focus<\/h2>

The Roundup litigation has been a significant uncertainty factor for Bayer for several years. The current proceedings in Missouri are therefore particularly relevant, as the hearing addresses the proposed settlement framework intended to cover a substantial portion of the outstanding litigation.<\/p>

The market reacted positively ahead of the hearing. The Bayer stock stood at EUR 49.36 in late Monday morning trading, up around 2.5%<\/strong>.<\/p>

The hearing itself does not yet eliminate the legal uncertainty. The next important step will be the court’s decision on whether the settlement receives final approval.<\/p>

Analyst Consensus<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t<\/tr>
Analyst Consensus<\/th>Current<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t
Recommendation <\/b><\/td>ADD <\/b><\/td><\/tr>
Number of Analysts <\/b><\/td>18<\/td><\/tr>
Average Price Target <\/b><\/td>approx. EUR 58<\/td><\/tr>
Upside Potential<\/b><\/td>+21%<\/b><\/td><\/tr>
Highest Price Target<\/b><\/td>EUR 70<\/td><\/tr>
Lowest Price Target<\/b><\/td>EUR 46<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
Source: MarketScreener, September 14, 2026.<\/em><\/div>
<\/div>

Analyst sentiment toward Bayer has recently developed more constructively.<\/strong><\/p>

Recent adjustments also point in a more positive direction. Barclays raised its price target to EUR 70 on September 8 and confirmed its “Overweight” rating<\/strong>, while the Deutsche Bank maintained its buy recommendation with a price target of EUR 60 on September 10<\/strong>.<\/p>

Technical Picture: Bayer Tests Resistance at EUR 50<\/h2>

The current chart shows that Bayer stock continues to consolidate after the strong upward movement in June and July<\/strong>.<\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\"Bayer_1Day\"\/\t<\/a>\t\t\t\t

\n\t\t\t\t\t\t\t\t\t
Source: TradingView, as of September 14, 2026.<\/em><\/div>
<\/div>

The RSI (14) stands at around 58<\/strong>, signaling constructive momentum without an overbought signal. The MACD momentum is near neutral<\/strong> and reflects the recent consolidation phase.<\/p>

Key Takeaway<\/h2>

Bayer is approaching a key technical resistance zone while Roundup litigation enters another critical phase.<\/strong><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Bayer moves into focus ahead of the Roundup hearing. The stock approaches EUR 50 while legal risks and technical levels remain important.<\/p>\n","protected":false},"author":2,"featured_media":2171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[151],"tags":[431,329,407],"aktie":[],"class_list":["post-9431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-update","tag-bayer","tag-pharmaceutical-industry","tag-umbrella"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=9431"}],"version-history":[{"count":3,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9431\/revisions"}],"predecessor-version":[{"id":9445,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9431\/revisions\/9445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media\/2171"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=9431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=9431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=9431"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=9431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}